Health
Takeda To Keep Pushing for China Biotech Partnerships, CEO Says
- Japanese drugmaker has licensed from two Chinese drugmakers
- Christophe Weber sees costs coming down, revenue picking up
This article is for subscribers only.
Takeda Pharmaceutical Co. will keep up efforts to forge partnerships with Chinese biotech companies, as the drugmaker scouts for promising drug candidates to bolster its pipeline, Chief Executive Officer Christophe Weber said.
The Japanese pharmaceutical company recently struck a deal with Ascentage Pharma Group International that gives it an option to market a therapy for blood cancer globally. This follows approval in the US and Europe for another cancer drug called Fruzaqla Takeda licensed from Hutchmed China Ltd. “We should remain very open of potential partnerships with Chinese biotech,” Weber said in an interview.